A. Taamma

2.2k total citations · 1 hit paper
19 papers, 1.8k citations indexed

About

A. Taamma is a scholar working on Oncology, Otorhinolaryngology and Cancer Research. According to data from OpenAlex, A. Taamma has authored 19 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Otorhinolaryngology and 6 papers in Cancer Research. Recurrent topics in A. Taamma's work include Cancer Treatment and Pharmacology (7 papers), Head and Neck Cancer Studies (6 papers) and Synthesis and Biological Activity (5 papers). A. Taamma is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Head and Neck Cancer Studies (6 papers) and Synthesis and Biological Activity (5 papers). A. Taamma collaborates with scholars based in France, Netherlands and Spain. A. Taamma's co-authors include Esteban Cvitkovic, Éric Raymond, Stephen G. Chaney, José Jimeno, Étienne Brain, J. L. Misset, M. Riofrio, Alejandro Yovine, Jean‐Pierre Armand and Carmen Kahatt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

A. Taamma

19 papers receiving 1.7k citations

Hit Papers

Oxaliplatin: A review of preclinical and clinical studies 1998 2026 2007 2016 1998 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oxaliplatin: A review of preclinical and clinical studies
    1998 527 citations Éric Raymond, Stephen G. Chaney et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Taamma France 14 1.1k 867 354 321 256 19 1.8k
G. Veerman Netherlands 20 1.1k 1.0× 730 0.8× 347 1.0× 635 2.0× 236 0.9× 52 1.9k
Reinhard von Roemeling United States 23 728 0.7× 626 0.7× 212 0.6× 774 2.4× 606 2.4× 72 2.0k
Yasuo Ejima Japan 20 379 0.3× 394 0.5× 205 0.6× 332 1.0× 215 0.8× 49 1.3k
G. Frasci Italy 22 1.3k 1.2× 976 1.1× 178 0.5× 400 1.2× 315 1.2× 97 1.9k
Dean Lim United States 24 971 0.9× 417 0.5× 461 1.3× 706 2.2× 330 1.3× 72 2.1k
Clet Niyikiza United States 15 1.4k 1.3× 3.0k 3.5× 264 0.7× 585 1.8× 176 0.7× 29 3.8k
M.E.L. van der Burg Netherlands 27 961 0.9× 417 0.5× 664 1.9× 452 1.4× 187 0.7× 69 2.4k
G. N. Hortobágyi United States 23 1.7k 1.6× 543 0.6× 154 0.4× 573 1.8× 962 3.8× 106 2.7k
Tetsuhiko Shirasaka Japan 24 2.4k 2.2× 1.9k 2.2× 845 2.4× 749 2.3× 294 1.1× 102 3.5k
Marie-Christine Étienne-Grimaldi France 27 1.3k 1.2× 508 0.6× 106 0.3× 722 2.2× 343 1.3× 82 1.9k

Countries citing papers authored by A. Taamma

Since Specialization
Citations

This map shows the geographic impact of A. Taamma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Taamma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Taamma more than expected).

Fields of papers citing papers by A. Taamma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Taamma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Taamma. The network helps show where A. Taamma may publish in the future.

Co-authorship network of co-authors of A. Taamma

This figure shows the co-authorship network connecting the top 25 collaborators of A. Taamma. A scholar is included among the top collaborators of A. Taamma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Taamma. A. Taamma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Delord, J.P., Nadine Houédé, Ahmad Awada, et al.. (2010). First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2504–2504. 33 indexed citations
2.
Hilgers, Werner, Sandrine Faivre, Jérôme Alexandre, et al.. (2006). A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Investigational New Drugs. 24(4). 311–319. 13 indexed citations
3.
Zelek, Laurent, Alejandro Yovine, Étienne Brain, et al.. (2006). A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. British Journal of Cancer. 94(11). 1610–1614. 77 indexed citations
4.
Yovine, Alejandro, M. Riofrio, Jean‐Yves Blay, et al.. (2004). Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients. Journal of Clinical Oncology. 22(5). 890–899. 261 indexed citations
5.
Louvet, Christophe, Thierry André, Jean‐Marie Tigaud, et al.. (2002). Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients. Journal of Clinical Oncology. 20(23). 4543–4548. 237 indexed citations
6.
Kesteren, Charlotte van, Esteban Cvitkovic, A. Taamma, et al.. (2001). A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemotherapy and Pharmacology. 48(6). 459–466. 11 indexed citations
7.
Taamma, A., J. L. Misset, M. Riofrio, et al.. (2001). Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors. Journal of Clinical Oncology. 19(5). 1256–1265. 137 indexed citations
8.
Delaloge, Suzette, Alejandro Yovine, A. Taamma, et al.. (2001). Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity. Journal of Clinical Oncology. 19(5). 1248–1255. 136 indexed citations
9.
Delaloge, Suzette, A. Taamma, Nadia Chouaki, et al.. (2000). Pilot Study of the Paclitaxel, Oxaliplatin, and Cisplatin Combination in Patients With Advanced/Recurrent Ovarian Cancer. American Journal of Clinical Oncology. 23(6). 569–574. 29 indexed citations
10.
Kesteren, Charlotte van, Esteban Cvitkovic, A. Taamma, et al.. (2000). Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.. PubMed. 6(12). 4725–32. 72 indexed citations
11.
Fandi, Abderrahim, M. Bachouchi, N. Azli, et al.. (2000). Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type. Journal of Clinical Oncology. 18(6). 1324–1330. 144 indexed citations
12.
Hasbini, Ali, Abderrahim Fandi, Nadia Chouaki, et al.. (1999). Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype. Annals of Oncology. 10(4). 421–425. 42 indexed citations
13.
14.
Raymond, Éric, Stephen G. Chaney, A. Taamma, & Esteban Cvitkovic. (1998). Oxaliplatin: A review of preclinical and clinical studies. Annals of Oncology. 9(10). 1053–1071. 527 indexed citations breakdown →
15.
Fandi, Abderrahim, A. Taamma, N. Azli, et al.. (1997). Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. Head & Neck. 19(1). 41–47. 15 indexed citations
16.
Trandafir, Lucia, A. Taamma, François Lokiec, et al.. (1997). Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Anti-Cancer Drugs. 8(8). 763–766. 2 indexed citations
17.
18.
19.
Fandi, A., A. Taamma, P. Armand, et al.. (1994). [Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects].. PubMed. 81(7). 571–86. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Veerman Breakdown of academic impact, for papers by Reinhard von Roemeling Breakdown of academic impact, for papers by Yasuo Ejima Breakdown of academic impact, for papers by G. Frasci Breakdown of academic impact, for papers by Dean Lim Breakdown of academic impact, for papers by Clet Niyikiza Breakdown of academic impact, for papers by M.E.L. van der Burg Breakdown of academic impact, for papers by G. N. Hortobágyi Breakdown of academic impact, for papers by Tetsuhiko Shirasaka Breakdown of academic impact, for papers by Marie-Christine Étienne-Grimaldi
Rankless by CCL
2026